恩格列净治疗儿童糖原贮积病Ib型中性粒细胞减少的系统评价与Meta分析
该系统评价与Meta分析纳入6项非随机研究共177例儿童GSD-Ib患者,评估恩格列净对中性粒细胞减少的疗效与安全性。所有研究均报告恩格列净治疗后中性粒细胞计数改善(ANC>1.5),4项研究中性粒细胞减少缓解率>80%且均显示G-CSF减量或停用,不良事件轻微,乳酸酸中毒最严重。但多数研究存在严重或极严重偏倚风险,结论需谨慎解读。
要点
- 恩格列净可改善儿童GSD-Ib患者中性粒细胞计数并减少G-CSF使用。
- 不良事件少,乳酸酸中毒为最严重不良事件。
- 证据多来自非随机研究且偏倚风险高,结论仅为初步。
核心结论
- 恩格列净在儿童GSD-Ib中性粒细胞减少治疗中显示出有希望的疗效与安全性,但证据受研究设计和异质性限制,应视为初步结论。
研究设计与样本
- 遵循2020 PRISMA指南的系统评价与Meta分析,检索PubMed、Embase和Web of Science(2015-2025年),末次检索2025年5月16日。
- 纳入患者<18岁、GSD-Ib伴中性粒细胞减少且接受恩格列净治疗的研究,研究类型包括随机对照试验、观察性研究和病例系列。
- 共纳入6项非随机研究,n=177,52%为男性,平均年龄6.7岁。
- 采用ROBINS-I V2评估偏倚风险,GRADE评估证据确定性,Meta分析根据异质性选择固定或随机效应模型。
主要发现
- 所有研究报告恩格列净治疗后中性粒细胞计数改善(ANC>1.5)。
- 4项研究中性粒细胞减少缓解率>80%,所有研究均显示G-CSF减量或停用。
- 不良事件轻微,乳酸酸中毒为最严重的不良事件。
- 两项研究偏倚风险低,三项研究存在极严重偏倚风险。
关键数值与推荐
- 主要疗效结局定义为中性粒细胞减少的缓解,安全性结局包括总体不良事件。
- 纳入标准:患者<18岁、GSD-Ib伴中性粒细胞减少、接受恩格列净治疗;排除非英文、2015年前发表及非原始研究。
临床怎么用
- 恩格列净可作为儿童GSD-Ib中性粒细胞减少的潜在治疗选择,尤其用于减少G-CSF用量。
- 临床使用时需监测中性粒细胞计数和G-CSF需求变化,并警惕乳酸酸中毒等不良事件。
- 因证据等级有限,治疗决策应结合患者具体情况并谨慎评估获益与风险。
局限性
- 多数纳入研究为非随机设计,根据ROBINS-I工具评为严重或极严重偏倚风险,显著限制汇总结果的可靠性和可解释性。
- 研究间存在异质性,结果应视为初步结论并谨慎解读。
- 需要进一步随机试验,特别是测量1,5-AG的试验,以确认恩格列净作为G-CSF有希望疗法的角色。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Glycogen storage disease type Ib (GSD-Ib) is a rare genetic disorder causing neutropenia and neutrophil dysfunction in children. G-CSF has been the primary treatment, but emerging data support the potential of empagliflozin, an SGLT2 inhibitor, as a promising investigational option. This systematic review and meta-analysis assess its feasibility, efficacy and safety in paediatric GSD-Ib patients. METHODS: Following the 2020 PRISMA guidelines, a systematic search was conducted in PubMed, Embase and Web of Science (2015-2025). The last search was performed on 16 May 2025. The inclusion criteria were patients <18 years with GSD-Ib and neutropenia treated with empagliflozin. Eligible study types included randomized controlled trials (RCTs), observational studies and case series. Non-English, pre-2015 and non-primary research were excluded. Bias was assessed using ROBINS-I V2, and certainty via GRADE. Meta-analyses used fixed or random effects depending on heterogeneity. The primary efficacy outcome was defined as resolution of neutropenia, and safety outcome included overall adverse events. RESULTS: Six non-randomized studies (n = 177; 52% male; mean age 6.7) met the inclusion criteria. Two studies showed low risk of bias; three were critically biased. All reported improved neutrophil counts (ANC > 1.5) after empagliflozin treatment. Four studies had >80% resolution of neutropenia; all showed G-CSF reduction or discontinuation. Adverse events were minimal; lactic acidosis was the most serious. CONCLUSIONS: Empagliflozin shows promise in treating neutropenia in paediatric GSD-Ib patients, with encouraging efficacy and safety. However, findings are limited by study design and heterogeneity. The majority of included studies were non-randomized and rated as having a serious or critical risk of bias according to the ROBINS-I tool. This substantially limits the reliability and interpretability of pooled outcomes. These results should therefore be viewed as preliminary and interpreted with caution. Further randomized trials, especially those measuring 1,5-AG, are needed to confirm empagliflozin's role as promising therapy in G-CSF.
引用
- Iwasyk E, Jin R, Tuzzolino F, et al. Efficacy and safety of empagliflozin for treating neutropenia and neutrophil dysfunction in paediatric patients with glycogen storage disease type Ib: A systematic review and meta-analysis. Br J Clin Pharmacol. 2025. PMID: 41024628. doi:10.1002/bcp.70294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。